Myelodysplastic Syndromes (MDS)
Clinical Trials and Children
Until recently, children were rarely included in studies of medical treatments. As a result, much is still unknown about how children respond to drugs, some biologics (such as gene therapy) and medical devices. According to the U.S. Food and Drug Administration (FDA), only 20-30% of approved drugs have actually been labeled for use in children.
Transplantation for Older MDS Patients
Topic(s)
Bone Marrow Transplant
Living Well with Bone Marrow Failure
Myelodysplastic Syndromes (MDS)
Presenter(s)
Nandita Khera, MD, MPH
Linda Burns, MD
In this discussion, Dr. Nandita Khera of Associate Professor of Mayo Clinic and Dr. Linda Burns Sr. Scientific Director of CIBMTR discuss which treatments are available to older MDS patients.
Certain Patients With Myelodysplastic Syndromes, Acute Leukemia at Higher Risk of Severe COVID-19 Illness
Original Publication Date
Article Source
External Web Content
Myelodysplastic syndromes (MDS) and neutropenia were both found to be strong, independent predictors of severe COVID-19 illness in patients with acute leukemia or MDS who developed COVID-19, according to data from the American Society of Hematology (ASH) RC COVID-19 Registry for…
mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS
Original Publication Date
Article Source
External Web Content
The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines…
Clinical Trials in Depth
Clinical trials Clinical trials: Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease.
Blood and marrow transplants (BMT) help people with advanced myelodysplastic syndromes (MDS)
Original Publication Date
Article Source
External Web Content
Not enough people have access to life-saving transplant Although BMT is the only known cure for MDS, many people aren’t aware of BMT or think that they’re too old to have one because of its side effects. Using smaller doses of therapy with BMT have made it safer. Now a new study…
Andrew Brunner
Institution
Harvard Medical School
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
About
Dr. Andrew Brunner is an Assistant Professor, Medicine at Harvard Medical School and Assistant in Medicine at the Center for Leukemia at Massachusetts General Hospital in Boston, Massachusetts. His research is focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. He is involved in clinical trials for all stages of MDS with an overall goal of tailoring treatment to improve the outcomes of these patients.
Dale Schaar, MD, PhD
Institution
Rutgers Cancer Institute of New Jersey
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Eloy Roman, MD
Institution
Lakes Research
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)